Cargando…

Commentary: Retinopathy of prematurity: Where do we stand?

Detalles Bibliográficos
Autores principales:	Parchand, Swapnil M, Gangwe, Anil, Agrawal, Deepshikha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482945/ https://www.ncbi.nlm.nih.gov/pubmed/34304193 http://dx.doi.org/10.4103/ijo.IJO_1288_21

Ejemplares similares

Commentary: Deep learning in retinopathy of prematurity: Where do we stand?
por: Sen, Parveen, et al.
Publicado: (2022)

Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: A survey among the members of Indian Retinopathy of Prematurity Society
por: Gangwe, Anil, et al.
Publicado: (2021)

Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity
por: Parchand, Swapnil M, et al.
Publicado: (2021)

Successful treatment of aggressive posterior retinopathy of prematurity with diode laser in ocular albinism: A case report
por: Gangwe, Anil B, et al.
Publicado: (2019)

Retinopathy of Prematurity among Preterm Newborn Admitted to the Neonatal Care Unit in a Tertiary Care Centre: A Descriptive Cross-sectional Study
por: Bastola, Pradeep, et al.
Publicado: (2023)

Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity
por: Gangwe, Anil Babanrao, et al.
Publicado: (2021)

Commentary: Functional outcome after successful laser for retinopathy of prematurity – Where we stand?
por: Rishi, Ekta, et al.
Publicado: (2019)

Comment on: Evaluation of clinical profile and screening guidelines of retinopathy of prematurity in an urban level III neonatal intensive care unit
por: Gangwe, Anil Babanrao, et al.
Publicado: (2023)

Commentary: COVID-19 and ocular inflammation: Where do we stand and where are we headed?
por: Sheth, Jay U
Publicado: (2021)

Commentary: Viral serology testing before cataract surgery: Where do we stand?
por: Nayak, Bhagabat, et al.
Publicado: (2022)

Post-cataract surgery cluster endophthalmitis due to multidrug-resistant Pseudomonas aeruginosa: A retrospective cohort study of six clusters
por: Parchand, Swapnil M, et al.
Publicado: (2020)

Commentary: Systemic versus imaging biomarkers for diabetic macular oedema – Where do we stand?
por: Rana, Vipin, et al.
Publicado: (2021)

Impact of COVID-19 pandemic and national lockdown on ocular trauma at a tertiary eye care institute
por: Agrawal, Deepanshu, et al.
Publicado: (2021)

Gene therapy for arthritis – where do we stand?
por: Chernajovsky, Yuti
Publicado: (2005)

Commentary: Retinoblastoma management—Where are we and where do we go from here?
por: Shanmugam, P Mahesh
Publicado: (2020)

Perioperative care in perforation peritonitis: Where do we stand?
por: Garg, Rakesh
Publicado: (2013)

Fluoroquinolone resistance in bacterial isolates from ocular infections: Trend in antibiotic susceptibility patterns between 2005-2020
por: Chatterjee, Samrat, et al.
Publicado: (2022)

Surgical trials in India, where do we stand?
por: Khajanchi, M
Publicado: (2022)

Topical therapy of psoriasis: Where do we stand?
por: Thappa, DM, et al.
Publicado: (2017)

Mechanical Thrombectomy- Where Do We Stand Now ?
por: Chakraborty, Debabrata, et al.
Publicado: (2022)

Hyperbaric oxygen therapy promotes neurogenesis: where do we stand?
por: Mu, Jun, et al.
Publicado: (2011)

Immunosenescence and Cytomegalovirus: where do we stand after a decade?
por: Pawelec, Graham, et al.
Publicado: (2010)

Platelet Rich Plasma in Androgenic Alopecia: Where do we Stand?
por: Godse, Kiran
Publicado: (2014)

Treatment of Diabetes in Bullous Pemphigoid Patients: Where Do We Stand?
por: Alexandre, Maria Inês, et al.
Publicado: (2023)

Commentary: Biosimilars in the treatment of retinopathy of prematurity
por: Soni, Tanvi, et al.
Publicado: (2023)

Calcium and Vitamin D in the Regulation of Energy Balance: Where Do We Stand?
por: Soares, Mario J., et al.
Publicado: (2014)

Risk stratification tools in prostate cancer, where do we stand?
por: Clinckaert, Andries, et al.
Publicado: (2021)

Recent translational research: antiangiogenic therapy for breast cancer – where do we stand?
por: Miller, Kathy D
Publicado: (2004)

Neoadjuvant targeted therapy for advanced renal cell carcinoma: Where do we stand?
por: Grivas, Nikolaos K.
Publicado: (2019)

Fulminant scleral abscess secondary to infected scleral buckle with Moraxella species
por: Gangrade, Aashish, et al.
Publicado: (2019)

Where Do We Stand?
Publicado: (1891)

Commentary: Antivascular endothelial growth factor and retinopathy of prematurity
por: Dudani, Ajay Indur, et al.
Publicado: (2019)

Commentary: Cataract in retinopathy of prematurity - Prevention is the best cure
por: Sen, Parveen, et al.
Publicado: (2022)

Commentary: Are we there yet? Role of anti-vascular endothelial growth factor and laser in the management of retinopathy of prematurity
por: Sindal, Manavi D, et al.
Publicado: (2021)

Intrauterine exposures, pregnancy estrogens and breast cancer risk: where do we currently stand?
por: Lagiou, Pagona
Publicado: (2006)

Commentary: Parental involvement in retinopathy of prematurity care: An individualized approach
por: Sindal, Manavi D, et al.
Publicado: (2021)

Commentary: we can tell where it hurts, but can we tell where the pain is coming from or where we should manipulate?
por: Brady, O’Dane, et al.
Publicado: (2013)

Genetic-based Risk Assessment for Hepatocellular Carcinoma in Patients with Hepatitis C: Where Do We Stand?
por: Choi, Jonggi, et al.
Publicado: (2016)

Gravity: where do we stand ?
por: Peron, Roberto, et al.
Publicado: (2016)

Sperm DNA fragmentation testing: where we stand in 2017
por: Tandon, Salil
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_h90v7uocsgnberr8tum75dklrh